ERBB2 and breast cancer: It is widely recognized that the success of targeted therapies depends on identification of appropriate predictive biomarkers, such as HER2 for trastuzumab treatment in breast cancer and Bcr-Abl for imatinib or dasatinib in chronic myeloid leukaemia treatment [9, 10].